Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

Tobacco-Related Carcinoma Clinical Trial

Official title:

Promising Methods to Decrease Delay Discounting and Reduce Relapse to Smoking

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04297332
• Other study ID #: I 82819
• Secondary ID: NCI-2020-00697I
• Status: Terminated
• Phase: N/A
• Start date: January 1, 2020
• Est. completion date: December 28, 2023

Study information

• Verified date: February 2024
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial studies the main and interactive effects of episodic future thinking and future thinking priming tasks on helping participants to quit smoking. Episodic future thinking and future thinking priming tasks may decrease delay discounting rates and reduce relapse to smoking and help participants quit smoking.

Description:

PRIMARY OBJECTIVE:

I. To quantify the main and interactive effects of the episodic future thinking (EFT) and future thinking priming (FTP) tasks on delay discounting rate, latency to relapse, and multiple abstinence and self-regulation measures among smokers (n=76) who call a busy Quitline to quit smoking.

OUTLINE: Participants are randomized to 1 of 4 arms.

ARM I: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM II: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM III: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM IV: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: December 28, 2023
• Est. primary completion date: December 28, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Smoke >= 8 cigarettes daily

• Planning to quit in the next 14 days

• No regular use of other tobacco products

• Access to the internet

• In possession of a smartphone with text messaging capabilities

• In possession of an email address accessible at least every other day

Exclusion Criteria:

• Unable or unwilling to provide consent

• Unable to provide data to the research team after the quit date

• Current use of bupropion or varenicline

• Drinking >= 20 alcoholic drinks per week

• Use of drugs of abuse in the past 30 days

• Living in the same household as a participant already enrolled in this study

Related Conditions & MeSH terms

• Tobacco-Related Carcinoma

Intervention

Behavioral:
• Behavioral Intervention
Complete active episodic thinking task
• Behavioral Intervention
Complete active future thinking priming task
• Behavioral Intervention
Complete control episodic future thinking task
• Behavioral Intervention
Complete control future thinking priming task

Other:
• Informational Intervention
Provided with Forever Free relapse prevention booklet

Drug:
• Nicotine Replacement
Receive nicotine patches, gum, or lozenges

Other:
• Telephone-Based Intervention
Receive coaching call

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Delay discounting rate	Assessed with the 5-Trial Adjusting Delay Discounting.	Baseline, and 4 and 12 weeks after quit date
Primary	Latency to relapse	Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.	Baseline, assessed up to 12 weeks
Secondary	Latency to first relapse	Defined as the number of days until first relapse (any smoking for seven consecutive days). Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.	up to 12 weeks
Secondary	Number of days abstinent	Will be evaluated by cox proportional-hazards survival model analyses.	Up to 12 weeks
Secondary	7-day point prevalence abstinence rates	Will be evaluated by cox proportional-hazards survival model analyses.	At 4 and 12 weeks after quit date
Secondary	Attentional, motor, and non-planning impulsiveness	Assessed with the Barratt Impulsiveness Scale.	Up to 12 weeks
Secondary	Behavioral inhibition and behavioral activation	Assessed with the Behavioral Avoidance/Inhibition scales.	Up to 12 weeks
Secondary	Self-control	Assessed with the Brief Self-Control Survey.	Up to 12 weeks
Secondary	Ability to regulate behavior to achieve goals	Assessed with the Short Self-Regulation Questionnaire.	Up to 12 weeks